Biohaven Ltd is a high-risk pharmaceutical company based in the United States of America. Specializing in ESG-focused treatments, Biohaven is dedicated to developing innovative therapies across various therapeutic areas, including immunology, neuroscience, and oncology. Their product pipeline consists of treatments targeting diseases such as neuromuscular and metabolic diseases, cancer, obsessive-compulsive disorder, and more. With a Risk Rating Score of 32.3, Biohaven is a leading player in the pharmaceutical industry.